Physician profile
Cory Ls Offutt
NPI 1811330806
$1,998.28
in general payments reported to CMS, 2019-2025
27 companies · $37.10 in 2025
The $37.10 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $17.67 · 2021: $127 · 2022: $107 · 2023: $668 · 2024: $504 · 2025: $37.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.60 | 2021-2025 | |
| Pfizer INC. | $298.19 | 2019-2024 | |
| Novo Nordisk INC | $234.47 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $215.58 | 2019-2024 | Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $128.77 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $115.04 | 2019-2023 | Breztri, Farxiga |
| Exact Sciences Corporation | $89.54 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $75.54 | 2019-2024 | Repatha, Otezla |
| Abbott Laboratories | $71.61 | 2023-2024 | Freestyle Libre |
| Philips North America LLC | $57.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $49.76 | 2019 | |
| Harmony Biosciences LLC | $41.24 | 2024 | |
| Eisai INC. | $40.13 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $26.81 | 2024 | Rexulti |
| Allergan, INC. | $26.72 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $26.23 | 2023 | Xywav |
| Apria Healthcare LLC | $25.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.71 | 2019 | |
| Advanced Respiratory, INC | $19.28 | 2019 | |
| Valinor Pharma, LLC | $18.38 | 2024 | Movantik |
| Phathom Pharmaceuticals, INC. | $17.03 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $16.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2023 | Eliquis |
| Shire North American Group INC | $14.03 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.89 | 2019 | |
| Glaxosmithkline, LLC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cory Offutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.